Quoin Pharmaceuticals Targets Peeling Skin Syndrome with First-Ever IND Submission

Event summary

  • Quoin Pharmaceuticals submitted an IND application for QRX003 to treat Peeling Skin Syndrome (PSS), marking the first-ever IND submission for this rare disease.
  • The submission is supported by positive clinical data from an ongoing investigator-led pediatric study showing significant improvements in skin, sleep, and quality of life.
  • Quoin plans to initiate a Phase 2 study in the second half of 2026, recruiting 6-8 pediatric and adult patients in the US and Europe.
  • QRX003 is also being developed for Netherton Syndrome, making PSS the second indication for the drug.

The big picture

Quoin Pharmaceuticals is positioning itself as a leader in rare dermatologic diseases by expanding the development of QRX003 into a second indication. The company's focus on orphan diseases with no approved treatments aligns with the growing emphasis on addressing unmet medical needs in niche patient populations. With both QRX003 and QRX009 targeted for clinical testing in 2H 2026, Quoin is rapidly building a pipeline that could become commercially valuable in the rare dermatology space.

What we're watching

Clinical Progress
How the Phase 2 study results will validate QRX003's efficacy in PSS and support its broader platform potential.
Regulatory Pathway
Whether the FDA's review and approval process for QRX003 in PSS will face any hurdles, given the rarity of the disease.
Pipeline Expansion
The pace at which Quoin can advance QRX003 and QRX009 across additional rare dermatologic indications.